Showing 581 - 600 results of 743 for search '(( 2020 a decrease ) OR ( 10 (((peer OR per) decrease) OR (((nn decrease) OR (mean decrease)))) ))*', query time: 0.21s Refine Results
  1. 581

    Trends in prescribing and outcomes in obese versus non-obese patients receiving rivaroxaban therapy: an observational study using real-world data by Alalawneh, Majdoleen

    Published 2023
    “…Results The number of patients initiated on rivaroxaban therapy significantly increased from 152 (3.3%) in 2015 to 1342 (28.9%) in 2020 (p <0.001). Within BMI categories, a similar increasing trend was observed in underweight, normal, and overweight patients, while from 2018 to 2020, there was a decreasing trend in rivaroxaban prescribing in all obese classes. …”
    Get full text
    Get full text
  2. 582
  3. 583
  4. 584
  5. 585
  6. 586
  7. 587
  8. 588
  9. 589

    Trends and Appropriateness of Sodium-glucose Co-transporter 2 Inhibitors Use in Qatar by Zaghloul, Nancy

    Published 2023
    “…Consistently, sulfonylurea prescriptions declined between 2017 and 2020. Empagliflozin prescribing showed an increase over dapagliflozin, which decreased by the end of 2018. …”
    Get full text
  10. 590
  11. 591
  12. 592
  13. 593
  14. 594
  15. 595
  16. 596

    Three dimensional evaluation of the skeletal and temporomandibular joint changes following stabilization splint therapy in patients with temporomandibular joint disorders and mandi... by Ahmed, Madiha Mohammed Saleh

    Published 2023
    “…Results: The treatment period with SS therapy was 10.07 ± 3.1 months. The deviated chin was improved in 69.23% of the sample; the range of improvement was > 0 mm ≤ 3.9 mm. …”
    Get full text
    Get full text
    Get full text
  17. 597
  18. 598
  19. 599
  20. 600